Right ventricular protein expression profile in end-stage heart failure

被引:17
|
作者
Su, Yan Ru [1 ]
Chiusa, Manuel [1 ]
Brittain, Evan [1 ]
Hemnes, Anna R. [2 ]
Absi, Tarek S. [3 ]
Lim, Chee Chew [1 ]
Di Salvo, Thomas G. [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Div Cardiovasc Med, Nashville, TN 37212 USA
[2] Vanderbilt Univ, Sch Med, Div Pulm Med & Crit Care, Nashville, TN 37212 USA
[3] Vanderbilt Univ, Sch Med, Dept Surg Sci, Div Cardiac Surg, Nashville, TN 37212 USA
关键词
right ventricle; human heart failure; proteomics; protein expression; PULMONARY-HYPERTENSION; DILATED CARDIOMYOPATHY; MITOCHONDRIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; EXTRACELLULAR PROTEINS; MOLECULAR-MECHANISMS; MYOCARDIAL PROTEOME; PRESSURE-OVERLOAD; DESMIN MUTATIONS; GENE;
D O I
10.1086/682219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little is known about the right ventricular (RV) proteome in human heart failure (HF), including possible differences compared to the left ventricular (LV) proteome. We used 2-dimensional differential in-gel electrophoresis (pH: 4-7, 10-150 kDa), followed by liquid chromatography tandem mass spectrometry, to compare the RV and LV proteomes in 12 explanted human hearts. We used Western blotting and multiple-reaction monitoring for protein verification and RNA sequencing for messenger RNA and protein expression correlation. In all 12 hearts, the right ventricles (RVs) demonstrated differential expression of 11 proteins relative to the left ventricles (LVs), including lesser expression of CRYM, TPM1, CLU, TXNL1, and COQ9 and greater expression of TNNI3, SAAI, ERP29, ACTN2, HSPB2, and NDUFS3. Principal-components analysis did not suggest RV-versus-LV proteome partitioning. In the nonischemic RVs (n = 6), 7 proteins were differentially expressed relative to the ischemic RVs (n = 6), including increased expression of CRYM, B7Z964, desmin, ANXA5, and MIME and decreased expression of SERPINA1 and ANT3. Principal-components analysis demonstrated partitioning of the nonischemic and ischemic RV proteomes, and gene ontology analysis identified differences in hemostasis and atherosclerosis-associated networks. There were no proteomic differences between RVs with echocardiographic dysfunction (n = 8) and those with normal function (n = 4). Messenger RNA and protein expression did not correlate consistently, suggesting a major role for RV posttranscriptional protein expression regulation. Differences in contractile, cytoskeletal, metabolic, signaling, and survival pathways exist between the RV and the LV in HF and may be related to the underlying HF etiology and differential posttranscriptional regulation.
引用
收藏
页码:481 / 497
页数:17
相关论文
共 50 条
  • [21] Management of end-stage heart failure
    Moulopoulos, SD
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1996, 19 (06): : 327 - 328
  • [22] Management of End-Stage Heart Failure
    Murthy, Sandhya
    Lipman, Hannah I.
    PRIMARY CARE, 2011, 38 (02): : 265 - +
  • [23] Hospice and end-stage heart failure
    Huiskes, BL
    Elatre, WA
    Heywood, JT
    CIRCULATION, 2003, 108 (17) : 556 - 556
  • [24] The effect of hemodialysis on right ventricular functions in patients with end-stage renal failure
    Akkaya, Mehmet
    Erdogan, Ercan
    Sag, Saim
    Ari, Hasan
    Turker, Yasin
    Yilmaz, Mustafa
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2012, 12 (01): : 5 - 10
  • [25] Telomerase in end-stage heart failure
    Liu, SC
    Wang, SS
    Wu, MZ
    Wu, DC
    Yu, FJ
    Chen, WJ
    Yu, MF
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 37 (01) : 221 - 221
  • [26] Dilemmas in end-stage heart failure
    Carol ChenScarabelli
    Louis Saravolatz
    Benjamin Hirsh
    Pratik Agrawal
    Tiziano MScarabelli
    Journal of Geriatric Cardiology, 2015, 12 (01) : 57 - 65
  • [27] Total right ventricular exclusion improves left ventricular function in patients with end-stage congestive right ventricular failure
    Takagaki, M
    Ishino, K
    Kawada, M
    Ohtsuki, S
    Hirota, M
    Tedoriya, T
    Tanabe, Y
    Nakai, M
    Sano, S
    CIRCULATION, 2003, 108 (10) : 226 - 229
  • [28] Effect of cardiac resynchronization therapy on left ventricular fibrosis-related mRNA expression profile in patients with end-stage heart failure
    Sayour, A. A.
    Olah, A.
    Ruppert, M.
    Barta, B. A.
    Polos, M.
    Benke, K.
    Hartyanszky, I
    Szenthe, K.
    Banati, F.
    Szathmary, S.
    Merkely, B.
    Radovits, T.
    EUROPEAN HEART JOURNAL, 2020, 41 : 809 - 809
  • [29] Total right ventricular exclusion improves left ventricular function in patients with end-stage congestive right ventricular failure
    Takagaki, M
    Ishino, K
    Kawada, M
    Hirota, M
    Tedoriya, T
    Tanabe, Y
    Nakai, M
    Sano, S
    CIRCULATION, 2002, 106 (19) : 418 - 418
  • [30] Effect of right ventricular lead location on response to cardiac resynchronization therapy in patients with end-stage heart failure
    Haghjoo, Majid
    Bonakdar, Hamid Reza
    Jorat, Mohammad Vahid
    Fazelifar, Amir Farjam
    Alizadeh, Abolfath
    Ojaghi-Haghjghi, Zahra
    Esmaielzadeh, Maryam
    Sadr-Ameli, Mohammad Ali
    EUROPACE, 2009, 11 (03): : 356 - 363